Semaglutide Improved Brain Function in Obese Mice by Reshaping Gut Bacteria and Reducing Inflammation | Research

The takeaway

Semaglutide reversed obesity-induced cognitive impairment in mice by restoring healthy gut microbiota composition and reducing pro-inflammatory cytokines, suggesting the gut-brain axis as a key mechanism.

Gut-brain axis mechanism identified
Semaglutide reversed obesity-induced changes in gut bacteria that correlated directly with cognitive function and inflammation, providing the first evidence that gut microbiota reshaping may be a key mechanism behind GLP-1 drugs' brain benefits.

What the researchers found

In obese mice fed a high-fat diet for 12 weeks then treated with semaglutide:

- Cognitive function improved significantly on the Morris water maze test

- Pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) were reduced

- Gut microbiota changes were reversed: Akkermansia, Muribaculaceae, Coriobacteriaceae_UCG_002, and Clostridia_UCG_014 (all decreased by obesity) were restored; Romboutsia, Dubosiella, and Enterorhabdus (increased by obesity) were reduced

Correlation analysis revealed:

- Muribaculaceae and Clostridia_UCG_014 positively correlated with cognitive function

- Romboutsia and Dubosiella negatively correlated with cognitive function

- Romboutsia positively correlated with inflammatory cytokines (TNF-α, IL-6, IL-1β)

- Clostridia_UCG_014 negatively correlated with inflammatory cytokines

Why it matters

With millions of people now taking semaglutide for diabetes and obesity, understanding how it affects the brain is critically important. This study provides mechanistic evidence that semaglutide's cognitive benefits may operate through the gut-brain axis — by restoring healthy gut bacteria and reducing inflammation. This could help explain the emerging clinical observations that GLP-1 medications appear to protect against dementia and cognitive decline.

How the study worked

Twenty-four C57BL/6J male mice were divided into three groups of 8: normal-chow diet (NCD), high-fat diet (HFD), and HFD + semaglutide (Sema). After establishing obesity with HFD, mice received semaglutide or saline for 12 weeks. Cognitive function was assessed with the Morris water maze test. Serum pro-inflammatory cytokines were measured. Gut microbiota composition was analyzed using 16S rRNA gene sequencing. Correlation analysis linked microbiota changes to cognitive and inflammatory outcomes.

What this study cannot tell us

This is an animal study with a small sample size (8 mice per group), which limits statistical power and generalizability. Mouse gut microbiota and cognitive processes differ from humans. The Morris water maze tests spatial memory specifically and does not capture the full range of cognitive functions. Correlation between microbiota and outcomes does not prove causation — the bacteria may be bystanders rather than drivers. The 12-week timeframe may not reflect long-term effects. No dose-response analysis was performed.

How to read the evidence

This is a preclinical animal study with a small sample size (n=24 mice total). While it provides interesting mechanistic insights linking gut microbiota to cognitive outcomes, the findings are preliminary and require validation in larger animal studies and human clinical trials.

When this study was published

Published in 2024, this study is very recent and addresses one of the hottest topics in GLP-1 research — how these medications affect brain function. It adds mechanistic depth to the growing human observational evidence linking semaglutide to cognitive protection.

The bigger picture

The gut-brain axis is increasingly recognized as a critical pathway linking metabolic health to brain function. This study adds semaglutide to the growing list of interventions that can modulate this axis. The finding that specific gut bacteria correlate with both cognitive function and inflammation provides a mechanistic framework for understanding why obesity impairs cognition and how GLP-1 drugs might prevent or reverse this. It also opens the door to combining semaglutide with probiotic strategies for enhanced neuroprotection.

Questions still open

Does semaglutide produce similar gut microbiota changes in humans, and do those changes correlate with cognitive improvements?
Would supplementing semaglutide treatment with probiotics containing Akkermansia or Muribaculaceae enhance cognitive benefits?
Is the gut microbiota reshaping a cause of semaglutide's cognitive benefits, or simply a parallel effect of weight loss and reduced inflammation?

Common questions

Can semaglutide improve brain function by changing gut bacteria?

In this mouse study, yes. Semaglutide restored beneficial gut bacteria (like Akkermansia) that had been depleted by obesity, reduced inflammation-promoting bacteria, and improved performance on memory tests. The researchers found that specific gut bacteria were directly correlated with both cognitive performance and inflammation levels, suggesting the gut-brain axis is a key pathway for semaglutide's cognitive effects. However, these are mouse findings that need to be confirmed in humans.

What is Akkermansia and why does it matter?

Akkermansia muciniphila is a beneficial gut bacterium that helps maintain the gut lining and has been linked to better metabolic health. In this study, obesity caused Akkermansia levels to drop, while semaglutide treatment restored them. Higher Akkermansia levels have been associated with reduced inflammation and better metabolic outcomes in multiple studies, making its restoration by semaglutide a potentially important finding for understanding the drug's broader health benefits.

Read the original research

Effects of semaglutide on gut microbiota, cognitive function and inflammation in obese mice.

PeerJ, 12, e17891

View on PubMed ↗Publisher’s paper ↗

Citation

Feng, Jing; Teng, Zhenjie; Yang, Yu; Liu, Jingzhen; Chen, Shuchun. (2024). Effects of semaglutide on gut microbiota, cognitive function and inflammation in obese mice.. PeerJ, 12, e17891. https://doi.org/10.7717/peerj.17891